One of the main scientific gaps in pet supplement development compared to the human sector lies in the continued extrapolation of human data without sufficient species-specific validation. For certain ingredients with a long-standing, generic traditional use in both humans and pets, such as chamomile, this approach can be acceptable, provided quality and safety requirements are fully met. However, demonstrated safety and efficacy in humans do not automatically translate into an open runway for the pet market.

This depends strongly on whether the mode of action is comparable between humans and animals and whether the same or equivalent biomarkers can be identified and measured. Biomarker validation remains limited in companion animals. While human dietary supplements benefit from well-established biomarkers to track outcomes such as inflammation, oxidative stress, or metabolic health, these markers are far less standardized or validated in pets, making robust study design and claim substantiation more challenging.

In addition, dosage recommendations require careful, species-specific evaluation. Human intake levels cannot simply be scaled down; they must be derived using proprietary data or scientifically sound, peer-reviewed conversion protocols. This is essential because animals have distinct metabolic, physiological, and microbiome profiles, which vary significantly across species, breeds, life stages, and health conditions.

Finally, ingredient quality, safety, and traceability are non-negotiable. I would only work with ingredients produced in FSSC or GMP+ certified facilities to ensure the highest standards of safety, consistency, and full traceability across the value chain. This also enables harmonized product development for both the US and EU markets. While regulatory classifications differ, quality expectations are increasingly aligned and well-established ingredients like lemon balm, when properly dosed and documented, can meet requirements in both regions. The key lies in adjusting claims language and documentation, not the formulation itself. Importantly, in the US, regulatory treatment depends not only on the ingredient itself but also on the final product format: powders and liquids are often positioned as supplements, whereas functional chews may be regulated as pet foods or treats, depending on composition and claims. The key lies in adjusting claims language, delivery format, and documentation, not necessarily the active ingredients.

Bridging these gaps will require greater investment in collaborative research, open-access data, and a much stronger integration of veterinary science with nutritional innovation.

Today’s market still suffers from inconsistent labeling, unverified claims, and a lack of species-specific evidence, all of which undermine trust, especially among veterinarians and well-informed pet owners. If we want to elevate pet supplements to the same level of credibility as human products, we need a stronger, harmonized framework that defines what constitutes a real supplement versus a treat, outlines clear pathways for functional claims, and requires companies to disclose sourcing, standardization, and manufacturing certifications.

This shift doesn’t have to mean over-regulation. Rather, it’s about raising the baseline: ensuring that what’s on the label reflects what’s in the product, that safety and dosage are adapted to the target species, and that efficacy claims are supported by transparent, accessible data, even if based on traditional use or adapted from human science.

In the long run, this will benefit the entire value chain: brands that invest in quality will stand out, veterinarians will feel more confident recommending products, and consumers will be empowered to make informed, responsible choices for their pets.

Industry forecasts put the global pet supplements market on a strong growth trajectory over the next decade, with projected CAGRs commonly in the mid-5% to low-7% range across major market studies. These trends reflect rising pet humanization, preventive health focus, and e-commerce adoption (1).

But this steady growth in the pet supplement market is not guaranteed for everyone. Global forecasts estimate a CAGR of 5–7% through 2030, with the premium segment and functional categories (e.g., mobility, calming, gut health, aging) outpacing general growth.

However, this rising tide won’t lift all boats. Success will increasingly depend on scientific rigor, regulatory readiness, ethical sourcing, and smart go-to-market strategies. Brands relying on vague claims, low-quality sourcing, or opportunistic marketing will struggle to maintain credibility as both consumer expectations and regulatory oversight increase.

Those who invest in species-specific science, certified manufacturing (e.g., GMP+, FSSC), transparent labeling, and targeted channel strategies, including DTC and veterinary partnerships, will define the future of this category.

Would I personally invest in pet supplements? Absolutely.
Just like in human health, I’m drawn to projects that focus on longevity, quality of life, and sustainability, not just symptom relief.

Pets are more than animals, they’re loyal companions. In a world shaped by aging populations, rising mental health concerns, and evolving family dynamics, their emotional and social importance only grows.

I believe pet supplements can play a vital role in supporting shared, healthy lifestyle routines — enhancing not only the pet’s vitality but also the well-being of the people who care for them. As we age, pets help us stay active, emotionally balanced, and socially connected. They are part of the family and in many cases, the most loyal member.

Supporting innovations that extend healthspan for both pets and their humans is not just a business case — it’s a mission I care about deeply.